About this trial
* To quantify the expression of Nuclear enriched abundant transcript 1 (NEAT1) and Anti-sense Non RNA in the INLK4 locus (ANRIL) to determine their potential role as non invasive diagnostic biomarkers in inflammatory bowel disease. * To evaluate the correlation between the studied biomarkers and both the clinical presentation of the patients and the inflammatory mediators like Nuclear factor κB (NF-KB) signaling pathway.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Newly histopathologicaly diagnosed IBD
Disqualifiers
Patients with serious complications as intestinal obstruction, perforation, polyps or colorectal carcinoma
Patients who are taking NSAIDs or Immunosuppressive drugs
Patients who are having other autoimmune disorders
Patients with Chronic infections as TB or other diseases
Trial population
Patients with inflammatory bowel disease
Trial design
Case-control
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
To quantify the expression of NEAT1 and ANRIL to determine their potential role as non invasive diagnostic biomarkers in inflammatory bowel disease.
Measure level of NEAT1 and ANRIL genes in blood samples of inflammatory bowel disease patients
Secondary outcomes
To evaluate the correlation between the studied biomarkers among the studied groups explored and both their clinical presentations and the inflammatory mediators like NF-KB signaling pathway.
To find the relation between the studied biomarkers (NEAT1 and ANRIL) and the inflammatory mediators like NF-KB signaling pathway.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: